RxDoctor Payments DataLook up a doctor →

Ari Rosenberg, MD

Hematology & Oncology · Chicago, ILNPI 1699017715

Payments from drug & device makers

$1,604,759in general payments, 2019–2025

Across 368 payments — averaging $4360.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma Global Development$493K
  • Janssen Research & Development, LLC$299K
  • AbbVie$176K
  • Beigene Switzerland GmbH$117K
  • Beigene, Ltd.$112K
  • EMD Serono Research & Development Institute, Inc.$96K
  • plus $310K from 17 others
$1,262in research payments, 2019–2025

Across 2 payments — averaging $631.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Global Development$1K

What the payments were for

  • Consulting fees$54,30582%
  • Speaking & faculty fees$7,93512%
  • Travel & lodging$1,4952%
  • Food & beverage$2,3304%
  • Education$500%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,604,759 in reported general payments places this provider in the 90th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$75,413
Medicare patients
207
Services billed
687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate25$521,677
CabometyxCabozantinib S-Malate24$494,782
TafinlarDabrafenib Mesylate11$157,985
Levothyroxine Sodium73$414
Gabapentin12$321
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Lenvima$10,322$521,67725 claims
Exelixis Inc.Cabometyx$92,137$494,78224 claims
NovartisTafinlar$2,625$157,98511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →